Leidos Holdings enters its August 4 earnings report at $115.60 — up 12% over the past month but still carrying the weight of a stock that has shed roughly 38% year-to-date, with bears freshly rebuilt and the Street's price-target deck cut to pieces.
The short-interest story has continued to develop since the earlier earnings-preview note. Bears added another 10% in a week, lifting short interest to 4.8% of the free float — a 22% increase over the past month. The pace is deliberate rather than panicked. Cost to borrow has climbed 62% over the same period to 0.56%, the highest level in the 30-day window, reflecting genuine new demand for borrowed shares ahead of the print. That said, the lending market is nowhere near stressed: availability runs at roughly 4,000% of short interest, meaning shares remain plentiful and there is no mechanical pressure on existing shorts. Options add a mild defensive tilt — the put/call ratio at 0.49 is about one standard deviation above its 20-day average of 0.45 — but this is hedging into a binary event, not a crowded bearish thesis.
The analyst community has moved decisively in one direction. Every firm in the recent-changes log has cut its price target, and two — Bank of America and Jefferies — downgraded outright earlier in the summer. Goldman Sachs lowered to $152 on July 14, maintaining Neutral. JP Morgan trimmed to $160 from $210 on July 13, holding Overweight. The pattern is consistent: bulls are staying bullish but reducing their numbers; neutrals are staying put at lower anchors. The mean target across the Street is $150.67 — roughly 30% above Friday's close — which on paper looks generous, but reflects targets set before a sustained de-rating rather than fresh conviction buys. Valuation multiples give the bull case some structural support: the EV/EBITDA sits at 7.3x, which has actually compressed about 0.1x over the week, and the PE of 8.8x has expanded 0.7 turns over the past month as the stock has recovered. The EV/EBIT factor score ranks at the 92nd percentile of the universe — the shares are cheap on an earnings-power basis.
The bear case centres on the near-term operational headline: the unwinding of the high-margin VA medical-exam contract, softer managed health services demand, and tougher year-on-year comparisons after the ENTRUST acquisition. The ORTEX short score at 39.9 has drifted higher over the past week — up from 38.4 a week ago — but remains in moderate territory and well below levels that would flag structural short pressure. Momentum is the clearest drag on the combined score: relative-strength readings across 91-day and 182-day windows are deeply negative, reflecting a stock that has consistently underperformed its sector over the first half of 2026.
Among close peers, the picture on Friday was mixed. KBR jumped 6.5% on the day — the strongest print in the peer group — while CACI added 4.3% and BAH rose 2.1%. On the week, however, the comparison was less favourable: PSN collapsed 24.7%, BAH slipped 3.9%, and most names in the group gave back ground even as LDOS held a 3.1% weekly gain. LDOS is neither the weakest nor the strongest name in the cohort, but it is the one with the most binary near-term setup.
The earnings history is the clearest anchor for what to watch next. The last Q1 print on May 5 produced a one-day move of -9.3% and a five-day follow-through of -13.7% — a sharp and sustained reaction that set the tone for the stock's underperformance through the summer. Whether August 4 produces a comparable or inverted move will depend on whether margin guidance and VA-contract commentary land better than the Street's already-reduced bar — which is ultimately the question the next few days will answer.
See the live data behind this article on ORTEX.
Open LDOS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
